Gaudium IVF and Women Health Ltd(GAUDIUMIVF)

NSE: GAUDIUMIVFBSE: 544709

₹ 94+1.84%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 684 crWebsite: www.gaudiumivfcentre.comUpdated: 24 Oct 2026

About

Gaudium IVF and Women Health runs a chain of IVF (in vitro fertilisation) fertility clinics in India, set up as large hub centres linked to smaller spoke centres, along with hospital and pharmacy services. In FY26 it reported revenue of 104.36 (Rs crore), and its network covered 7 hubs and 28 spokes across 9 states. The company listed on BSE and NSE on February 27, 2026, raising Rs. 90 Cr. As of Q1 FY27 the network had grown to 8 hubs and 28 spokes.^[1][2][3]

Business segments

Services revenue mix in FY26: IVF treatment 64%, hospital 31%, pharmacy 4%.^[2]
In Q1 FY27, management said the pharmacy and hospital businesses earn structurally lower margins than core IVF and are run to support the patient journey.^[3]

Clinic network

In FY26 the network had 7 hubs and 28 spokes across 9 states. A Srinagar hub was added in 2024.^[2]
As of Q1 FY27 the network had 8 hubs and 28 spokes, after the South Extension (New Delhi) hub opened on 16 July 2026.^[3]
The Patna centre moved to Kankarbagh, a medical hub that draws patients from across Bihar. The new site opened just before the Q1 FY27 call.^[3]

Key operating numbers

Clinical pregnancy success rate at first attempt was 62% in Q1 FY27, up from 58% in FY26.^[3][2]
Cumulative pregnancy success rate was 85% in Q1 FY27, the same as the multiple-attempt rate in FY26.^[3][2]
Ovum pick-up (OPU, egg retrieval) cycles: 367 in Q1 FY27 and 2,255 in FY26.^[3][2]
Average revenue per patient was ₹3.5 lakhs in Q1 FY27, compared with Rs. 2,97,998 in FY26.^[3][2]

Technology

AI embryology tools SiD and ERICA were integrated into clinical practice from 1 April 2026, in partnership with IVF 2.0 (US). The company says it is the first IVF chain in India to do so.^[3]
Early data in Q1 FY27 show about an 8% improvement in first-attempt success rates where the tools were used. Q4 FY26 data had shown an early 8-9% uplift.^[3][2]
A one-time pan-India marketing spend of ₹253.24 lakhs on SiD and ERICA was incurred in Q1 FY27.^[3]

Patients and international reach

International patients made up about 25-30% of the patient mix in Q1 FY27.^[3]
International spokes are operating in Paris, Nigeria and Sydney as of Q1 FY27.^[3]
As of FY26 the company had treated patients from 30+ countries, including the Middle East, UK, Canada, Africa, Indonesia, Australia and New Zealand.^[2]

Expansion and capex

The company plans 19 new centres funded by IPO proceeds: 10 hubs in FY27, 8 centres in FY28 and 1 centre in FY29.^[3]
Capex for the 10 FY27 hubs is ₹25 crores (₹2.5 crore per hub), funded from IPO proceeds and internal accruals.^[3]
The FY27 plan stated in Q4 FY26 included 3 new hubs in Delhi/NCR and 2 in Nagpur.^[2]
The board approved up to ₹15 crores for the Gaudium Women Hospital in Lucknow, funded from internal accruals. Commercial operations are expected in FY28-FY29.^[3]

Recent developments

Commercial operations began at the new IVF centre in Gurugram, Haryana (Civil Lines) on September 24, 2026.^[4]
The South Extension (New Delhi) hub opened on 16 July 2026, the first milestone of the 19-centre expansion.^[3]
The company listed on BSE and NSE on February 27, 2026, raising Rs. 90 Cr of fresh equity. Debt/equity fell to 0.16x in FY26 from 0.45x in FY25.^[2]

Market Cap

₹684 Cr

High / Low

₹164 / 70

Stock P/E

27.4

Price / Book

4.4

Book Value

₹21

EPS

₹3.4

No. of Shares

7.28 Cr

ROCE

20.2%

ROE

16.1%

OPM

34.0%

Debt / Equity

0.15

Sales

₹104 Cr

Net Profit

₹24 Cr

Promoter holding

71.3%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials